Claire S.
Three years of specialists, $14K spent, and still crashing after a mile walk. A phased immune-mitochondrial peptide protocol finally changed the trajectory.
A former Boston-qualifying marathoner who couldn't walk more than a mile without a 2-day crash. Six months later: 8-hour work days, 5-mile walks, and running again — for the first time in 3 years.
Three Years. $14,000. Still Crashing.
Claire is a 36-year-old freelance copywriter — formerly a marketing director at a creative agency and a sub-3:30 marathoner who had qualified for Boston. In March 2023, acute COVID ended her athletic life. Three years later, she still could not run. Walking more than a mile triggered post-exertional malaise that would leave her non-functional for 2–3 days. Most days she could work four hours before crashing. She had lost 8 lbs of lean mass from three years of forced inactivity and had been forced to reduce to part-time freelance work from a role she had loved.
In those three years, she had spent over $14,000 pursuing answers. Three cardiologists — POTS workup normal. Two rheumatologists — no autoimmune diagnosis. A neurologist — normal MRI. A $4,000 supplement stack. An AIP diet that provided marginal help. Low-dose naltrexone that improved sleep. And $6,000 with a prior functional medicine practitioner whose work she now questioned — mostly mold and tick-borne disease testing that hadn't changed anything.
She came to FLOA deeply skeptical of any new program after the prior FM disappointment — but asking the right question: was there a protocol specifically designed for immune dysregulation and mitochondrial dysfunction, that could be introduced safely given her MCAS sensitivity, with pharmacy-grade sourcing and clinical oversight throughout?
What 3 Years of Long-COVID Looked Like
- Post-exertional malaise triggered by walking more than 1 mile — 2–3 day crash duration
- Functional work envelope of 4 hours/day before PEM crash
- HRV chronically suppressed at 24 (resting HR 78–85 bpm vs. prior athletic baseline of 48 bpm)
- Deep sleep under 40 minutes/night; 8–9 hours of sleep that felt completely unrefreshing
- hs-CRP 4.8 mg/L and ESR 22 — sustained systemic inflammation for 3 years
- Ferritin 18 ng/mL — low-normal, reflecting chronic inflammatory depletion
- Flattened cortisol diurnal curve: AM cortisol 8 µg/dL with no meaningful rise — HPA axis dysregulation
- DHEA-S 88 µg/dL — low for age, adrenal insufficiency pattern
- Free T3 2.4 — low-normal thyroid function compounding fatigue
- MCAS symptoms: flushing, itching, chemical sensitivity — constraining supplement and medication options
- Lean mass loss of 8 lbs over 3 years from forced inactivity — sarcopenic drift without any exercise capacity to reverse it
- Deep skepticism of new protocols after $14K+ spent with minimal improvement — trust was earned, not assumed
Foundation First — A Phased Immune-Mitochondrial Approach
Comprehensive long-COVID and post-viral fatigue protocol expertise applied. Full immune, mitochondrial, and endocrine panel. HRV and dysautonomia assessment via Oura and symptom tracking. MCAS protocol review for peptide stack compatibility. LDN protocol optimization. Existing antihistamine regimen (cetirizine + famotidine) reviewed and preserved. Conservative pacing strategy designed before a single peptide was introduced.
BPC-157 at 250 mcg subQ daily introduced first and alone — before any immune-active or mitochondrial peptides. Rationale: gut barrier dysfunction and systemic inflammation are limiting factors on every downstream intervention. Peptides function as amplifiers; if the inflammatory environment is dysregulated, introducing immune-modulating peptides without this foundation risks unpredictable reactions. Introducing BPC-157 first also provided a 4-week tolerance observation window critical for a patient with MCAS sensitivity.
TA-1 at 1.6mg subQ twice weekly added after BPC-157 tolerance confirmed. Thymosin Alpha-1 modulates immune function rather than suppressing it — a critical distinction for long-COVID, where immune dysregulation (not deficiency) is the driver. It enhances T-cell maturation, NK cell activity, and regulatory immune balance without the immunosuppressive risk of corticosteroids. Conservative initial dosing with titration to full dose only after week 1 response assessed.
MOTS-c at 5mg subQ 3x/week introduced only after TA-1 tolerance confirmed at weeks 9–12. MOTS-c is a mitochondrial-derived peptide that regulates cellular energy metabolism, AMPK activation, and metabolic homeostasis — directly addressing the mitochondrial dysfunction that underlies post-COVID fatigue and PEM. Sequential introduction allowed any adverse response to be isolated to a specific agent rather than lost in a multi-peptide stack initiated simultaneously.
Given MCAS chemical sensitivity, pharmacy-grade sourcing from a licensed compounding pharmacy with certificates of analysis was non-negotiable — not a preference. Research-site peptides with unverified excipients and unknown purity profiles carry real MCAS reaction risk. All existing medications (LDN 4.5mg, H1/H2 antihistamines) preserved and maintained throughout. A conservative escalation gate was built in: any worsening of symptoms triggered protocol pause and reassessment before proceeding.
Anti-inflammatory, low-histamine nutritional framework aligned with MCAS profile. Protein target increased from her current 0.5g/lb to a therapeutic 0.8g/lb to support lean mass recovery within her energy envelope constraints. Strict pacing protocol maintained — no exercise progression until immune markers improved and HRV recovered. LDN preserved; supplement timing reorganized; sleep hygiene reinforced around existing architecture.
Phase by Phase
BPC-157 Only — Gut Symptoms Improving, No PEM Increase
BPC-157 phase initiated alone. Chronic gut looseness that had persisted for 3 years began resolving within the first two weeks. No increase in PEM — a critical early signal confirming good tolerance in a patient with chemical sensitivity. Subjective inflammation reduction noted. The absence of adverse response was itself meaningful data.
→ Gut symptoms improving; no PEM increase; MCAS tolerance confirmed
TA-1 Introduced — Mild Immune Activation, Then Stable
Thymosin Alpha-1 added at conservative dose after BPC-157 foundation phase. Mild fatigue increase in week 1 of TA-1 — immune activation response, expected and managed by the clinical team rather than alarming. Stabilized by week 2 as immune system began recalibrating. The team had pre-briefed Claire on this expected response — which prevented the kind of panic discontinuation that derails many long-COVID protocols.
→ TA-1 initiated; immune activation managed; stable by week 2
Brain Fog Lifting — MCAS Symptoms Reducing — Work Hours Expanding
TA-1 well-tolerated at full dose. MCAS symptoms reducing — less flushing, less itching — as systemic immune dysregulation began to modulate. hs-CRP dropped from 4.8 to 3.2 mg/L. Brain fog noticeably better. Functional work capacity expanded from 4 to 6 hours per day without a PEM crash — the first meaningful improvement in 3 years.
→ Work capacity 6 hrs; hs-CRP 3.2; brain fog improving; MCAS reducing
MOTS-c Added — HRV Rising — Walking Tolerance Expanding
MOTS-c introduced after TA-1 tolerance confirmed. HRV trending upward from 24 to 38 — the first significant autonomic recovery signal. Resting HR dropping from 82 to 72 bpm. PEM threshold rising: short walks of 1.5–2 miles now tolerated without a crash. Ferritin improved from 18 to 42 ng/mL — cellular energy substrate replenishing. The mitochondrial layer was working.
→ HRV 38; resting HR 72; 2-mile walks tolerated; ferritin 42
Running Reintroduced — 8-Hour Days — 3 Years of Decline Reversed
Full protocol stable. Gentle run/walk intervals reintroduced at month 5 — the first running in 3 years. Functional work envelope reached 8 hours without PEM crash. MCAS symptoms minimal. LDN dose reduced from 4.5mg to 3mg — the immune modulation from TA-1 reducing the LDN burden required. Walking tolerance reached 5+ miles. Running 30-minute intervals 3x/week by month 6.
→ Running restored; 8-hr work days; 5+ mi walks; LDN reduced; MCAS minimal
"Long-COVID is not a single disease. It is a convergence of immune dysregulation, mitochondrial failure, autonomic dysfunction, and gut barrier compromise — each reinforcing the others. The reason most protocols fail is that they target one pathway while leaving the others intact. The sequence here was intentional: gut barrier first, immune modulation second, mitochondrial enhancement third. Each layer had to be functional before the next could work. Introducing MOTS-c into an unmodulated immune environment would have been like tuning an engine with a broken fuel system."
What Changed at 6 Months
Running Restored
From unable to walk more than 1 mile without a multi-day crash — to running 30-minute run/walk intervals 3x/week by month 6. The identity outcome that mattered most to Claire.
Energy Envelope
Functional work capacity from 4 hours → 8 hours per day without PEM crash. Walking tolerance from under 1 mile → 5+ miles. PEM crash duration from 2–3 days → zero by month 6.
Inflammation Resolved
hs-CRP from 4.8 → 1.1 mg/L. ESR from 22 → 9. Three years of sustained systemic inflammation substantially resolved over 6 months of targeted immune modulation.
Autonomic Recovery
HRV from 24 → 52. Resting HR from 82 → 64 bpm — approaching her pre-illness athletic baseline of 48. Cortisol diurnal curve restored from flat to normal AM rise pattern.
Sleep Quality
Deep sleep from under 40 minutes → over 60 minutes per night. Refreshing sleep reported for the first time in 3 years. Sleep architecture normalized alongside autonomic and immune recovery.
Bloodwork & Hormones
Ferritin from 18 → 58 ng/mL. DHEA-S from 88 → 145 µg/dL. Cortisol diurnal curve restored. LDN dose reduced from 4.5mg → 3mg as immune modulation reduced LDN dependence.
| Category | What Changed |
|---|---|
| Running | Zero running capacity for 3 years → 30-min run/walk intervals 3x/week by month 6 |
| PEM Crashes | 2–3 day crashes triggered by a 1-mile walk → zero crashes at 5+ miles by month 6 |
| Work Capacity | 4 hours/day → 8 hours/day without cognitive or physical crash |
| Brain Fog | Largely resolved by month 2; cognitive performance approaching pre-illness baseline |
| MCAS Symptoms | Flushing, itching, chemical sensitivity — substantially reduced; protocol tolerated fully |
| Sleep | 8–9 hrs unrefreshing → genuine restorative sleep for the first time in 3 years |
| HRV | 24 → 52 — autonomic nervous system recovery progressing toward pre-illness range |
| LDN Dependence | 4.5mg → 3mg — immune modulation from TA-1 reducing pharmaceutical burden |
| Lean Mass | +3 lbs over 6 months — first reversal of the 3-year sarcopenic drift |
| Identity | Athletic engagement reclaimed — running again after 3 years of forced withdrawal |
"I'd seen every specialist. I'd spent $14,000 and three years trying to get my life back. Every time someone new told me they could help, I got my hopes up and was let down. I came to FLOA deeply skeptical. What was different was that they actually understood the mechanisms — why my immune system was dysregulated, why mitochondrial function mattered, why the sequence of the protocol mattered. They didn't rush me. They monitored everything. And six months later I ran for the first time in three years. I don't have words for what that meant."
Clinical Takeaways
Claire's case illustrates why long-COVID protocols fail when they treat the condition as a single-system problem. The conventional medical pathway she had exhausted — cardiology, rheumatology, neurology — is organized around organ systems, not the cross-system dysregulation that defines post-viral illness. Her POTS workup was normal. Her autoimmune panel was negative. Her MRI was clean. None of those findings meant she was well. They meant the problem was operating below the diagnostic threshold of each individual specialty.
The phased protocol sequence was not arbitrary. BPC-157 was introduced first because gut barrier dysfunction and systemic inflammation are rate-limiting factors for every downstream intervention. Thymosin Alpha-1 was introduced second because immune modulation had to precede mitochondrial enhancement — an unmodulated dysregulated immune environment would have created unpredictable responses to MOTS-c. MOTS-c was introduced third, after both prior phases had established tolerability and laid the biological groundwork for mitochondrial enhancement to actually function. Each layer amplified the next.
The MCAS sensitivity also shaped every decision. Pharmacy-grade sourcing was mandatory — not a preference — because research-site peptides carry unverified excipient profiles that carry real MCAS reaction risk. The conservative escalation gate, the preserved antihistamine protocol, and the pre-briefing on expected TA-1 immune activation responses were all part of managing this safely. The goal was never to move fast. It was to build function that would last.
If Long-COVID Has Taken Your Life — the Specialists Aren't Enough
Post-viral illness operates across systems simultaneously — immune, mitochondrial, autonomic, gut. A protocol that treats all of them, in the right sequence, with clinical oversight and pharmacy-grade compounds, is different from everything else you've already tried.
Individual results vary. This case study is for educational purposes only. © Dr. Jones DC — FLOA Protocol.